Alimera Sciences Inc (ALIM)
3.31
-0.32
(-8.82%)
USD |
NASDAQ |
Apr 25, 16:00
3.34
+0.03
(+0.91%)
After-Hours: 20:00
Alimera Sciences Enterprise Value: 242.48M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 242.48M |
April 23, 2024 | 240.38M |
April 22, 2024 | 237.77M |
April 19, 2024 | 227.30M |
April 18, 2024 | 232.53M |
April 17, 2024 | 238.29M |
April 16, 2024 | 239.86M |
April 15, 2024 | 237.77M |
April 12, 2024 | 236.72M |
April 11, 2024 | 254.00M |
April 10, 2024 | 248.76M |
April 09, 2024 | 251.38M |
April 08, 2024 | 250.33M |
April 05, 2024 | 254.00M |
April 04, 2024 | 256.61M |
April 03, 2024 | 259.23M |
April 02, 2024 | 259.23M |
April 01, 2024 | 254.00M |
March 28, 2024 | 256.61M |
March 27, 2024 | 256.61M |
March 26, 2024 | 255.04M |
March 25, 2024 | 261.33M |
March 22, 2024 | 260.80M |
March 21, 2024 | 262.90M |
March 20, 2024 | 256.09M |
Date | Value |
---|---|
March 19, 2024 | 264.47M |
March 18, 2024 | 261.85M |
March 15, 2024 | 272.84M |
March 14, 2024 | 260.80M |
March 13, 2024 | 252.43M |
March 12, 2024 | 252.95M |
March 11, 2024 | 249.81M |
March 08, 2024 | 260.28M |
March 07, 2024 | 256.61M |
March 06, 2024 | 255.04M |
March 05, 2024 | 250.33M |
March 04, 2024 | 247.19M |
March 01, 2024 | 246.67M |
February 29, 2024 | 237.77M |
February 28, 2024 | 227.30M |
February 27, 2024 | 235.67M |
February 26, 2024 | 229.39M |
February 23, 2024 | 228.87M |
February 22, 2024 | 225.72M |
February 21, 2024 | 222.58M |
February 20, 2024 | 230.44M |
February 16, 2024 | 231.48M |
February 15, 2024 | 230.44M |
February 14, 2024 | 227.30M |
February 13, 2024 | 250.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
50.79M
Minimum
May 12 2023
308.09M
Maximum
Aug 16 2023
113.68M
Average
91.58M
Median
Enterprise Value Benchmarks
Eli Lilly and Co | 718.54B |
NovaBay Pharmaceuticals Inc | 2.284M |
Palatin Technologies Inc | 18.43M |
iBio Inc | 16.49M |
Theriva Biologics Inc | -13.90M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -3.781M |
Revenue (Quarterly) | 26.31M |
Total Expenses (Quarterly) | 25.58M |
EPS Diluted (Quarterly) | -0.0722 |
Gross Profit Margin (Quarterly) | 86.22% |
Profit Margin (Quarterly) | -14.37% |
Earnings Yield | -64.74% |
Normalized Earnings Yield | -43.30 |